Risperidone in Adolescents With Schizophrenia: An Open Pilot Study
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To assess critically the short-term efficacy and safety of risperidone in adolescents with schizophrenia. METHOD: Subjects were adolescents who were attending a research day hospital as outpatients and who had received a diagnosis of schizophrenia. This was an open pilot study; after a 2-week washout period during which all psychotropic medications were gradually discontinued, subjects were treated with risperidone for 6 weeks. Dosage was regulated individually over a period of 3 weeks; starting dose was 2.0 mg/day followed by 1.0-mg increments every 2 days; maximum dose was not to exceed 10 mg/day. The main outcome measures included the Positive and Negative Syndrome Scale of Schizophrenia, the Brief Psychiatric Rating Scale, and the Clinical Global Impression. RESULTS: Ten adolescents between 11 and 18 years of age were enrolled in the study. Risperidone produced clinically and statistically significant improvement on the Positive and Negative Syndrome Scale for Schizophrenia. Brief Psychiatric Rating Scale, and Clinical Global Impression at doses ranging from 4.0 mg/day to 10.0 mg/day (mean = 6.6). There were no major adverse reactions associated with risperidone use. CONCLUSIONS: Risperidone appears to have been effective and well tolerated in this sample of adolescents with schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clozapine-induced agranulocytosis. incidence and risk factors in the united states
Alvir, J. M. J., Lieberman, J. A., Safferman, A. Z., Schwimmer, J. L., & Schaaf, J. A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199307153290303 · Cited by 967
Studies in the Childhood Psychoses I. Diagnostic Criteria and Classification
Kolvin, I. (1971) · British Journal of Psychiatry · doi:10.1192/bjp.118.545.381 · Cited by 468
Cited by
Effective Treatment for Mental Disorders in Children and Adolescents
Burns, B. J., Hoagwood, K., & Mrazek, P. J. (1999) · Clinical Child and Family Psychology Review · doi:10.1023/a:1021826216025 · Cited by 385
Practice Parameter for the Assessment and Treatment of Children and Adolescents With Schizophrenia
McClellan, J., & Stock, S. (2013) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.02.008 · Cited by 361
Treatment Recommendations for the Use of Antipsychotics for Aggressive Youth (TRAAY). Part II
PAPPADOPULOS, E., MACINTYRE, J. C., CRISMON, M. L., FINDLING, R. L., MALONE, R. P., DERIVAN, A., SCHOOLER, N., SIKICH, L., GREENHILL, L., SCHUR, S. B., et al. (2003) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200302000-00008 · Cited by 289
Findling, R. L., Aman, M. G., Eerdekens, M., Derivan, A., Lyons, B., & The Risperidone Disruptive Behavior Study Group (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.4.677 · Cited by 161
Second-Generation Antipsychotic Medications in Children and Adolescents
Cheng-Shannon, J., McGough, J. J., Pataki, C., & McCracken, J. T. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2004.14.372 · Cited by 152
Metadata
- Authors
- ARMENTEROS, J. L., WHITAKER, A. H., WELIKSON, M., STEDGE, D. J., & GORMAN, J.
- Venue
- Journal of the American Academy of Child & Adolescent Psychiatry
- Publisher
- Elsevier BV
- Published
- 1997-05
- Volume
- 36
- Issue
- 5
- Pages
- 694-700
- ISSN
- 0890-8567 (ISSN-L)
- OpenAlex
- W2093197498
- Cited by
- 150
- References
- 2
- FWCI
- 5.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risperidone in Adolescents With Schizophrenia: An Open Pilot Study. https://app.cochat.ai/papers/10.1097/00004583-199705000-00021
- The paper
- ARMENTEROS, J. L., WHITAKER, A. H., WELIKSON, M., STEDGE, D. J., & GORMAN, J. (1997). Risperidone in Adolescents With Schizophrenia: An Open Pilot Study. Journal of the American Academy of Child & Adolescent Psychiatry. https://doi.org/10.1097/00004583-199705000-00021
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.